Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBC Transfusion Thresholds in Acute Leukemia
NCT02086773Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Apr 2014
- Primary completion
- Sep 2015
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of red blood cell transfusion in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL) and 2 more, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Tolerance of low transfusion threshold as assessed by the percentage of participants who crossed over from the low arm to the high arm at 60 days. Started Apr 2014; status: completed.
02
Drugs
red blood cell transfusion
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)acute promyelocytic leukemia (APL)myelodysplastic syndrome (MDS)therapy-related myeloid neoplasm (t-MN)
Beyond the preview
Go deeper on NCT02086773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02086773.